Boehringer last night linked up a 1 billion dollar deal with a startup biotech which is important for their eye health portfolio. The company is to enhance their current phase 2a drug in eye health.
Once Boehringer get their phase 2 TRPC 6 channels inhibitor results for protection of kidneys which are already supported by last years human grown podocytes protection they will target NYR to add the drug to their kidney and heart portfolio on a license deal or takeover. Difference is we are now entering phase 2a so the risk is significantly derisked compared to their signing last night which is still in animal studies
https://www.biospace.com/business/boehringer-links-with-irish-drug-delivery-start-up-re-vana-in-1b-eye-deal
-
- There are more pages in this discussion • 272 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add to My Watchlist
What is My Watchlist?
